Abstract: Methods useful for inhibiting the release of interleukin-1 and for alleviating interleukin-1 mediated conditions, such as IL-1-mediated inflammation, comprising administration of an effective amount of a pharmaceutically acceptable antioxidant compound such as disulfiram, tetrakis [3-(2,6-di-tert-butyl-4-hydroxyphenyl)propionyloxy methyl]methane or 2,4-disobutyl-6-(N,N-dimethylaminomethyl)-phenol.

Abstract: This invention relates to certain novel di- and tetra-fluoro analogs of squalene and to their methods of use in lowering plasma cholesterol and in inhibiting squalene epoxidase in patients in need thereof.

Abstract: The present invention relates to a method of lowering blood glucose in a patient afflicted with diabetes mellitus comprising administering to said patient a therapeutically effective glucose lowering amount of a 4,4'-bis(2,6-di-alkyl-phenol). The present invention also relates to a process for making 4,4'-bis(2,6-di-alkyl-phenol).

Abstract: This invention relates to certain 5',5'-dihaloaristeromycin/adenosine derivatives which are useful in inhibiting AdoMet-dependent transmethylation and in the treatment of patients afflicted with neoplastic or viral disease states.

Abstract: This invention relates to certain aristeromycin/adenosine derivatives which are useful in inhibiting AdoMet-dependent transmethylation and in the treatment of patients afflicted with neoplastic or viral disease states.

Abstract: This invention relates to certain acetylenic, cyano and allenic aristeromycin/adenosine derivatives which are useful in inhibiting AdoMet-dependent transmethylation and in the treatment of patients afflicted with neoplastic or viral disease states.

Abstract: The present invention relates to a pharmaceutical composition in the form of a multiple-compression tablet comprising(a) a discrete zone made with Formulation (A) which comprises a carrier base material combined with a therapeutically effective decongestant amount of a sympathomimetic drug, or a pharmaceutically acceptable salt thereof, the carrier base material being a mixture of (i) one or more pharmaceutically acceptable water-soluble nonionic cellulose ethers in an amount from about 18% to about 50% by weight of Formulation (A), (ii) one or more pharmaceutically acceptable anionic surfactants in an amount from about 2% to about 20% by weight of Formulation (A), and (iii) one or more other pharmaceutically acceptable excipients, and(b) a discrete zone made with Formulation (B) which comprises a second carrier base material combined with a therapeutically effective antihistaminic amount of a piperidinoalkanol, or a pharmaceutically acceptable salt thereof, the second carrier base being a mixture of (i) calc

Abstract: Methods useful for inhibiting the release of Interleukin-1 and for alleviating interleukin-1 mediated conditions, such as IL-1 mediated inflammation, comprising administration of an effective amount of an alkylidenedithiobis(substituted)phenol, preferably, 4,4'-(isopropylidenedithio(bis(2,6-di-tert-butyl) phenol, generically known as probucol.

Abstract: The present invention relates to a method of lowering total serum cholesterol in a patient in need thereof comprising administering to said patient a therapeutically effective hypocholesterolemic amount of bis(3,5-di-tertiary-butyl-4-hydroxyphenylthio)methane.

Abstract: A pharamaceutical composition in solid unit dosage form comprising (a) a therapeutically effective amount of a piperidinoalkanol compound, or a pharmaceutically acceptable salt thereof, (b) pharmaceutically acceptable nonionic or cationic surfactant in an amount of from about 0.1% to about 6% by weight of the composition, and (c) pharmaceutically acceptable carbonate salt in an amount of from about 2% to about 50% by weight of the composition.

Abstract: The present invention relates to the use of bis(3,5-di-tertiary-butyl-4-hydroxyphenylthio)methane in treating atherosclerosis and/or hypercholesterolemia in patients suffering therefrom.

Abstract: This invention relates to pharmacologically-active novel compounds comprising .beta.-fluoromethylene-5-hydroxytryptophan and derivatives, to methods of inhibiting monoamine oxidase and to treating depression, and to pharmaceutical compositions containing the compounds.

Abstract: Methods useful for inhibiting the release of interleukin-1 and for alleviating interleukin-1 mediated conditions, such as IL-1-mediated inflammation, comprising administration of an effective amount of a pharmaceutically acceptable antioxidant compound such as disulfiram, tetrakis [3-(2,6-di-tert-butyl-4-hydroxyphenyl)propionyloxy methyl]methane or 2,4-di-isobutyl-6-(N,N-dimethylaminomethyl)-phenol.

Abstract: 2-(Fluoromethyl or chloromethyl)-2,5-diaminopentanoic acid, 2-(fluoromethyl or chloromethyl)-2,6-diaminohexanoic acid, and 2-fluoromethyl-2-amino-5-guanidinopentanoic acid, and certain derivatives thereof, are inhibitors of ornithine decarboxylase. Methods of preparing the compounds and derivatives are also described.

Abstract: This invention relates to an improvement in a process for making 4,4'-isopropylidenedithio-bis-(2,6-di-tertiarybutylphenol), which is effected by carrying out an electrocatalytic reduction of bis(3,5-di-tertiarybutyl-4-hydroxyphenol)polysulfide at a lead cathode in an acidic electrolyte medium.

Abstract: Disclosed herein is a novel compound, (L)-menthyl 2-oxo-4-phenylbutyrate, and an improved process for making and isolating a substantially pure compound of the structural formula: ##STR1## wherein Y is hydrogen or (L)-menthyl the improvement which comprises: (a) stereoselectively reducing (L)-menthyl 2-oxo-4-phenylbutyrate by contacting said compound with S-B-(3-pinanyl)-9 horabicyclo[3,3,1]nonone,(b) stereoselectively isolating (L)-menthyl-(R)-2-hydroxy-4-phenylbutyrate by crystallization, and optionally hydrolyzing the so obtained ester;and further comprises optionally esterifying the so obtained acid by contacting said acid with a C.sub.1 -C.sub.6 alkanol in presence of acid.

Abstract: This invention relates to pharmacologically-active novel compounds comprising .beta.-fluoromethylene-5-hydroxytryptophan and derivatives, to methods of inhibiting monoamine oxidase and to treating depression, and to pharmaceutical compositions containing the compounds.

Abstract: The compound, 2-chloro-4-((cyanomethyl)thiolphenyl N-methyl carbamate, is a therapeutic agent in the treatment of patients afflicted with carcinomas or lymphocytic leukemia.